Bernardo Sousa-Pinto1, João Almeida Fonseca2, Eva Rebelo Gomes3. 1. MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal; CINTESIS-Center for Health Technology and Services Research, Porto, Portugal; Laboratory of Immunology, Basic and Clinical Immunology Unit, Faculty of Medicine, University of Porto, Porto, Portugal. 2. MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal; CINTESIS-Center for Health Technology and Services Research, Porto, Portugal. 3. Immunoallergology Department, Centro Hospitalar do Porto EPE, Porto, Portugal. Electronic address: evamariasrg@yahoo.com.
Abstract
BACKGROUND: Patients reporting drug allergy are treated with second-line therapies, with possible negative clinical and health consequences. OBJECTIVE: To assess the prevalence of self-reported drug allergy. METHODS: We performed a systematic review of observational studies assessing the prevalence of self-reported drug allergy. We searched 4 electronic databases. From selected studies, we extracted data on self-reported drug allergy prevalence, study design, participants' demographic characteristics, reported clinical manifestations, and suspected culprit drugs. We performed a random-effects meta-analysis followed by a meta-regression. RESULTS: Fifty-three studies were included in the systematic review, assessing a total of 126,306 participants, of whom 8.3% (range across studies 0.7-38.5%) self-reported drug allergy. Cutaneous manifestations were reported by 68.2% of participants, and anaphylactic or systemic reactions were reported by 10.8%. Antibiotics, nonsteroidal anti-inflammatory drugs, and anesthetics were the most frequently reported culprit drug classes. The frequency of self-reported drug allergy was higher in female (11.4%) than in male (7.2%) patients, adults (10.0%) than in children (5.1%), and in studies in the medical setting (15.9% in inpatients, 11.4% in outpatients) than in the general population (5.9%). The meta-analysis rendered a pooled prevalence of 7.9% (95% confidence interval 6.4-9.6), and the meta-regression identified study region, participants' age group, and study setting as factors associated with significant heterogeneity. Confirmation tests (including skin, in vitro, and drug provocation tests) were performed in only 3 studies. CONCLUSION: The prevalence of self-reported drug allergy is highly variable and is higher in female patients, adults, and inpatients. To overcome this variability, further studies using confirmation tests are needed.
BACKGROUND:Patients reporting drug allergy are treated with second-line therapies, with possible negative clinical and health consequences. OBJECTIVE: To assess the prevalence of self-reported drug allergy. METHODS: We performed a systematic review of observational studies assessing the prevalence of self-reported drug allergy. We searched 4 electronic databases. From selected studies, we extracted data on self-reported drug allergy prevalence, study design, participants' demographic characteristics, reported clinical manifestations, and suspected culprit drugs. We performed a random-effects meta-analysis followed by a meta-regression. RESULTS: Fifty-three studies were included in the systematic review, assessing a total of 126,306 participants, of whom 8.3% (range across studies 0.7-38.5%) self-reported drug allergy. Cutaneous manifestations were reported by 68.2% of participants, and anaphylactic or systemic reactions were reported by 10.8%. Antibiotics, nonsteroidal anti-inflammatory drugs, and anesthetics were the most frequently reported culprit drug classes. The frequency of self-reported drug allergy was higher in female (11.4%) than in male (7.2%) patients, adults (10.0%) than in children (5.1%), and in studies in the medical setting (15.9% in inpatients, 11.4% in outpatients) than in the general population (5.9%). The meta-analysis rendered a pooled prevalence of 7.9% (95% confidence interval 6.4-9.6), and the meta-regression identified study region, participants' age group, and study setting as factors associated with significant heterogeneity. Confirmation tests (including skin, in vitro, and drug provocation tests) were performed in only 3 studies. CONCLUSION: The prevalence of self-reported drug allergy is highly variable and is higher in female patients, adults, and inpatients. To overcome this variability, further studies using confirmation tests are needed.
Authors: Gilbert Matte; Joseph Shuster; Chantal Guevremont; Phil Gold; Fabrice Leong; Zinquon Ngan; André Bonnici; Chris Tsoukas Journal: Can J Hosp Pharm Date: 2020-02-01
Authors: Guilherme S Lopes; Suzette Bielinski; Ann M Moyer; Debra J Jacobson; Liwei Wang; Ruoxiang Jiang; Nicholas B Larson; Virginia M Miller; Ye Zhu; Dana C Cavanaugh; Jennifer St Sauver Journal: BMJ Open Date: 2021-06-30 Impact factor: 3.006
Authors: Victor J Wu; Michael C Iloanya; Fernando L Sanchez; Charles R Billings; Michael J O'Brien; Felix H Savoie; William F Sherman Journal: Clin Orthop Relat Res Date: 2020-12 Impact factor: 4.755